-
Something wrong with this record ?
Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients
E. Dvořáčková, M. Šíma, J. Petrus, E. Klapková, P. Hubáček, J. Pozniak, J. Havlín, R. Lischke, O. Slanař
Language English Country Switzerland
Document type Journal Article
Grant support
MH CZ-DRO (Motol University Hospital, Prague, Czech Republic 00064203)
Ministry of Health
Cooperatio Program (research area PHAR)
Charles University
SVV 260523
Charles University
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung transplant recipients, to explore its covariates, and to propose an individualized dosing regimen. Ganciclovir was administered according to the protocol in a standardized intravenous dose of 5 mg/kg twice daily. Serum ganciclovir concentrations were monitored as a trough and at 3 and 5 h after dosing. Individual ganciclovir pharmacokinetic parameters were calculated in a two-compartmental pharmacokinetic model, while regression models were used to explore the covariates. Optimal loading and maintenance doses were calculated for each patient. In lung transplant recipients (n = 40), the median (IQR) ganciclovir total volume of distribution and clearance values were 0.65 (0.52-0.73) L/kg and 0.088 (0.059-0.118) L/h/kg, respectively. We observed medium-to-high inter-individual but negligible intra-individual variability in ganciclovir pharmacokinetics. The volume of distribution of ganciclovir was best predicted by height, while clearance was predicted by glomerular filtration rate. Bodyweight-normalized clearance was significantly higher in patients with cystic fibrosis, while distribution half-life was reduced in this subgroup. On the basis of the observed relationships, practical nomograms for individualized ganciclovir dosing were proposed. The dosing of ganciclovir in patients with cystic fibrosis requires special caution, as their daily maintenance dose should be increased by approximately 50%.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010021
- 003
- CZ-PrNML
- 005
- 20220425131651.0
- 007
- ta
- 008
- 220420s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics14020408 $2 doi
- 035 __
- $a (PubMed)35214140
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Dvořáčková, Eliška $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic
- 245 10
- $a Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients / $c E. Dvořáčková, M. Šíma, J. Petrus, E. Klapková, P. Hubáček, J. Pozniak, J. Havlín, R. Lischke, O. Slanař
- 520 9_
- $a The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung transplant recipients, to explore its covariates, and to propose an individualized dosing regimen. Ganciclovir was administered according to the protocol in a standardized intravenous dose of 5 mg/kg twice daily. Serum ganciclovir concentrations were monitored as a trough and at 3 and 5 h after dosing. Individual ganciclovir pharmacokinetic parameters were calculated in a two-compartmental pharmacokinetic model, while regression models were used to explore the covariates. Optimal loading and maintenance doses were calculated for each patient. In lung transplant recipients (n = 40), the median (IQR) ganciclovir total volume of distribution and clearance values were 0.65 (0.52-0.73) L/kg and 0.088 (0.059-0.118) L/h/kg, respectively. We observed medium-to-high inter-individual but negligible intra-individual variability in ganciclovir pharmacokinetics. The volume of distribution of ganciclovir was best predicted by height, while clearance was predicted by glomerular filtration rate. Bodyweight-normalized clearance was significantly higher in patients with cystic fibrosis, while distribution half-life was reduced in this subgroup. On the basis of the observed relationships, practical nomograms for individualized ganciclovir dosing were proposed. The dosing of ganciclovir in patients with cystic fibrosis requires special caution, as their daily maintenance dose should be increased by approximately 50%.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/000000026541738X $7 xx0222901
- 700 1_
- $a Petrus, Jakub $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
- 700 1_
- $a Klapková, Eva $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
- 700 1_
- $a Hubáček, Petr $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
- 700 1_
- $a Pozniak, Jiří $u Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
- 700 1_
- $a Havlín, Jan $u Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic $1 https://orcid.org/0000000276672634 $7 xx0093656
- 700 1_
- $a Lischke, Robert $u Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000253577562 $7 xx0058262
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 2 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35214140 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220420 $b ABA008
- 991 __
- $a 20220425131649 $b ABA008
- 999 __
- $a ind $b bmc $g 1784466 $s 1161219
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 14 $c 2 $e 20220213 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a MH CZ-DRO (Motol University Hospital, Prague, Czech Republic 00064203) $p Ministry of Health
- GRA __
- $a Cooperatio Program (research area PHAR) $p Charles University
- GRA __
- $a SVV 260523 $p Charles University
- LZP __
- $a Pubmed-20220420